Clinical Trials
132 trialsALT-101
Allterum Therapeutics, Inc
A Study to Investigate the Safety, Tolerability, PK, PD, and Efficacy of ONO-7018 in Patients With R/R NHL or CLL
Ono Pharmaceutical Co., Ltd.
Study to Investigate Intravenous Blinatumomab in Japanese Adult Participants With Newly Diagnosed Philadelphia-negative B-precursor Acute Lymphoblastic Leukemia (B-ALL)
Amgen
Study of QUAIL-100 in Pediatric and Young Adult Participants With High-Risk Hematologic Malignancies Who Have Received a Hematopoietic Stem Cell Transplantation
Laguna Biotherapeutics, Inc.
A Safety and Efficacy Study of CD-19 t-haNK in Patients With B-cell Acute Lymphoblastic Leukemia
ImmunityBio, Inc.
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Kura Oncology, Inc.
A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations
Novartis
Study of ALA-101 in Patients With CD19 Positive Non-Hodgkin Lymphoma and Leukemia.
Arovella Therapeutics Ltd
FT819 in Subjects With B-cell Malignancies
Fate Therapeutics
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Kura Oncology, Inc.
Cryopreserved MMUD BM With PTCy for Hematologic Malignancies
Ossium Health, Inc.
A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms
NextCure, Inc.
Study of NMS-03597812 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia
Nerviano Medical Sciences
A Phase 1 Study of WU-NK-101 in Patients With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)
Wugen, Inc.
A Study to Assess the Effect of CC-95251 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndromes
Bristol-Myers Squibb
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
BlossomHill Therapeutics
A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes
Celgene
Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS
Novartis
Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab
Genmab
Study of Radiolabeled Revumenib in Adults With Acute Leukemia
Syndax Pharmaceuticals
CYNK001AML01
Celularity Incorporated
Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
Vincerx Pharma, Inc.
Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies
Xencor, Inc.
BGB 3111 in Combination With Obinutuzumab in Participants With B-Cell Lymphoid Malignancies
BeiGene
Study of a New Intravenous Drug, Called S65487, in Patients With Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic Leukemia
Servier
A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDS
Cyclacel Pharmaceuticals, Inc.
A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma
Pfizer
LAM-002A/NHL
OrphAI Therapeutics
A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia
Syndax Pharmaceuticals
Study of SGI-1776, a PIM Kinase Inhibitor, in Subjects With Relapsed/Refractory Leukemias
Astex Pharmaceuticals, Inc.
A Safety and Efficacy Study of CC-90009 Combinations in Subjects With Acute Myeloid Leukemia
Celgene
A Phase I Safety, PK and PD Study of KW-2478 in Patients With Multiple Myeloma, Chronic Lymphocytic Leukaemia or B-cell Non-Hodgkin's Lymphoma
Kyowa Kirin Co., Ltd.
Blinatumomab in Combination With AMG 404 for the Treatment of Adults With Relapsed or Refractory B Cell Precursor ALL
Amgen
BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia in Children
Guangzhou Bio-gene Technology Co., Ltd
A Phase 1, Open-Label, Dose-Escalation & Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK & PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias Involving
Ipsen
A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001)
VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
A Study to Evaluate VIP152 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Syndrome
Vincerx Pharma, Inc.
FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies
Fate Therapeutics
First-in Human (FIH) Trial of ETH-155008 in Subjects With B-NHL, CLL/SLL and AML
Shengke Pharmaceuticals (Jiangsu) Limited, China
A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene
Ipsen
Study of IMC-EB10 in Participant With Leukemia
Eli Lilly and Company
Immunotherapy With CD19 CAR T-cells for B-Cell Leukemia
Kecellitics Biotech Company Ltd
A Study of APTO-253 in Patients With Relapsed or Refractory AML or MDS
Aptose Biosciences Inc.
Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant
Bellicum Pharmaceuticals
Safety/PK Study of Gene Modified Donor T Cell Infusion in Children With Recurrent Hem Malignancies After Allo Transplant
Bellicum Pharmaceuticals
CD7 CAR-T Cell Treatment of Relapsed/Refractory CD7+ T -Acute Lymphoblastic Leukemia/ Lymphoma
iCell Gene Therapeutics
Anti-CD33 CAR-T Cells for the Treatment of Relapsed/Refractory CD33+ Acute Myeloid Leukemia
iCell Gene Therapeutics
Zanubrutinib (BGB-3111) in Combination With Tislelizumab (BGB-A317) in Participants With B-cell Malignancies
BeiGene
Safety and Early Efficacy Study of TBX-2400 in Patients With AML or Myelofibrosis
Taiga Biotechnologies, Inc.
A Study to Investigate BAY2402234, a Dihydroorotate Dehydrogenase (DHODH) Inhibitor, in Myeloid Malignancies
Bayer